Rising Incidence of Systemic Lupus Erythematosus
May 17, 2022
Recent News
Read ArticleData from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.
SLE was diagnosed using the EULAR/ACR criteria and looked at patients seen between 1976–2018.
They identified a total of 188 incident SLE cases in 1976–2018 (mean age 46.3 yrs; 83% women).
Multimorbidity Burden in Rheumatoid Arthritis
May 17, 2022
Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.
Read Article
Tuesday Night Rheumatology: Spondyloarthritis Spectrum https://t.co/4QW8dNGJQq
Dr. John Cush @RheumNow ( View Tweet)
May 17, 2022
@RheumNowNews has already taken a shot at this but let us try : HOW MANY RITUXIMAB pts do you have on EVUSHELD pre exposure prophylaxis for #COVID19 @CCalabreseDO @PaulSaxMD @philipcrobinson @JYazdanyMD @DrPujaMehta1 @jeffsparks @zach_wallace_md @alhkim
Leonard Calabrese @LCalabreseDO ( View Tweet)
May 17, 2022
And now the paper that no one can find even if they are looking for it. On the relationship between disease activity and glucocorticoid disease. https://t.co/aT8I0jwQOJ@rheum_covid @ARD_BMJ https://t.co/7ntGLPdypJ
The COVID-19 Global Rheumatology Alliance @rheum_covid ( View Tweet)
May 17, 2022
Dr. Robert Rosenberg, a founding physician of Arthritis and Rheumatism Associates, is retiring after 44 years effective 5/31/22. ARA extends our deepest gratitude and sincerest thanks for his decades of service and exceptional patient care. We wish him well in his retirement. https://t.co/mYQODUk5VY
Arth and Rheum Assoc @ARARheum ( View Tweet)
May 17, 2022
At a time when most American doctors have never seen measles, I think we should stop calling things morbilliform.
Adam Cifu @adamcifu ( View Tweet)
May 17, 2022
Differential diagnosis of dysphagia - when due to autoimmune dz is called Autoimmune neurogenic dysphagia - causes include inflammatory myopathies,inclusion body myositis, myasthenia gravis, Guillain–Barre, MS, NMO, paraneoplastic neuropathies https://t.co/oA0cPVJ5pJ https://t.co/58MyQwmxhL
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 17, 2022
⭐️Ethics of placebo-controlled trials in PsA ➡️move toward active comparator designs. Need to use measures of deeper response (e.g., ACR 50, PASI100).
⭐️Assesing safety: LTE studies not adequate. Use of phase 4 studies or observational data but beware confounding by indication
Rheum Cat @rheum_cat ( View Tweet)
May 17, 2022
SARS-CoV-2-infected alveoli (specifically N protein-coding plasmid alone) induces IL-6 production. Also, COVID-19 Sera also induced IL-6, moreso in those w/ severe disease. anti-N Ab promotes IL-6 production & may lead to cytokine storm https://t.co/jfPNwZM0g8 https://t.co/FwIs11i2qc
Dr. John Cush @RheumNow ( View Tweet)
May 17, 2022
Tonight!: Join us for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A.
7pm ET | Join on Zoom or watch LIVE on RheumNow Twitter, LinkedIn and Facebook.https://t.co/Y6MtCItIxw https://t.co/ysRM3cWyYa
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 17, 2022
Data from Scleroderma Lung Study (CTX vs MMF in PSS) shows that early progression of ILD by CXR scoring (≥ 2% at 12 or 24 months) experienced significantly worse long-term survival than those with stable Xrays (P = .014). https://t.co/BVy0WEE6G8 https://t.co/e6NN7nxNDt
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 17, 2022
24 week, Phase II RCT of baricitinib in 314 active #SLE patients showed significant reductions in levels of dsDNA, IgG, Sm & ACL Abs; but had no effect on C3/C4, RNP, SSA, SSB. Changes in dsDNA did not correlate with SRI-4 responses though.https://t.co/cF6rHbtvf9 https://t.co/zXnUImaLHF
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 17, 2022
Acute Inflammatory Responses Needed to Resolve Chronic Pain
May 16, 2022
Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.
Read Article
Bimekizumab Development Delayed by FDA
May 16, 2022
UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).
Read Article
FDA has approved baricitinib (Olumiant) for the Treatment of Certain Hospitalized Patients with COVID-19 who require supplemental O2, mechanical ventilation, ECMO. Rec dose: 4-mg once daily for 14 days or until hospital discharge https://t.co/RiEp01tc0v https://t.co/f3RvUAzdRp
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 16, 2022
Cool NEJM Case of Spinal Gout in 82-yr-old woman with 3-wk hx of severe LBP, rigors, anorexia, incomplete urination. Hx of PsA, CKD, CHF treated w/ Humira, HCQ, diuretics. Imaging tophi in spine, responded to steroids and allopurinol. https://t.co/JgH2bPsDeu https://t.co/RAPNxohe55
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 16, 2022
New podcast available on Methotrexate Monitoring. Download wherever you get your podcasts.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.https://t.co/TQiUMdS4R0 https://t.co/vgejiV3hUl
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 16, 2022
Study of 198 RMD pts, vaccinated 91% JAKi and 80% MTX mono pts were Ab+ for spike protein. Adjusting MTX or JAKi did not significantly alter the immunogenicity (S1 spike Abs). DMARD adjustments w/ COVID-19 VAX may not be needed. https://t.co/ebw172M5I4 https://t.co/vjXqTbuD5t
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 16, 2022
ASCORE: Seropositivity Favors Abatacept Drug Survival
The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 16, 2022
Can You Reduce Frequency of Methotrexate Monitoring?https://t.co/TnXZVCTv10 https://t.co/4q8sWwQ5aC
Links:
Dr. John Cush @RheumNow ( View Tweet)
May 16, 2022
From the blog
Interactions of the gut microbiota in humans promote the release of a variety of metabolites with profound effects on human health and immune regulation. These metabolites and compounds derived from the microbiota exert inflammatory and anti-inflammatory effects in the intestinal tissues and systemically.
Psoriatic disease is a multisystem condition with primarily skin and joint manifestations. Significant comorbidities, or related conditions, such as depression, cardiovascular diseases, inflammatory bowel disease common to psoriatic disease can further modify treatment decisions.
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they?
Read Post
Podcasts
Methotrexate Monitoring (5.13.2022)May 13, 2022
RNL 2022 - Psoriatic Arthritis AdvancesMay 11, 2022- What Is JAKne (5.6.2022)May 06, 2022
Tuesday Night Rheumatology- RA - Improving Future TherapyMay 04, 2022- $30 Billion And Counting (4.29.2022)Apr 29, 2022
Therapeutic Updates
Expert Perspectives on the Pathophysiology of SLE
Sponsored by GSK US Medical Affairs
May 01, 2022
Dr. Anca Askanase, Professor of Medicine and Director of the Lupus Center, Division of Rheumatology, Columbia University, takes us through the pathophysiology of SLE as we understand it today.
Read PostThe Science Behind a JAK Inhibitor for the Treatment of Ankylosing Spondylitis(AS)
Sponsored by AbbVie Medical Affairs
May 01, 2022
Read for an overview of results from SELECT-AXIS 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory AS patients.
Read Post